TWIST1 hypermethylation is observed in pancreatic cancer

Sen-Yo,Manabu; Suehiro,Yutaka; Kaino,Seiji; Sakaida,Isao

doi:10.3892/br.2012.25

TWIST1 hypermethylation is observed in pancreatic cancer

Authors:
- Manabu Sen-Yo
- Yutaka Suehiro
- Seiji Kaino
- Isao Sakaida
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan, Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
Published online on: October 18, 2012 https://doi.org/10.3892/br.2012.25
Pages: 31-33

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the growing evidence demonstrating that TWIST1 is a noteworthy tumor biomarker, little is known about the clinical significance of TWIST1 methylation in human primary pancreatic cancer. In the present study, the association of TWIST1 methylation with clinicopathological characteristics was examined in human primary pancreatic cancer. Primary pancreatic cancer specimens and corresponding healthy pancreatic non‑tumorous tissues from 33 patients with pancreatic cancer were used. Methylation levels of TWIST1 were compared with clinicopathological characteristics. The TWIST1 methylation level was higher in pancreatic cancer compared to corresponding non‑neoplastic pancreatic tissues. The mean TWIST1 methylation was 66.7% for pancreatic cancer tissue and 15.0% for corresponding nonneoplastic pancreatic tissue (P=0.0004). These results suggested that TWIST1 methylation is a useful biomarker for the screening of pancreatic cancers. Studies using independent data sets are required to confirm these findings.

View Figures

View References

1.	Warshaw AL and Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med. 326:455–465. 1992. View Article : Google Scholar : PubMed/NCBI
2.	Niederhuber JE, Brennan MF and Menck HR: The National Cancer Data Base report on pancreatic cancer. Cancer. 76:1671–1677. 1995. View Article : Google Scholar : PubMed/NCBI
3.	Hebrok M, Wertz K and Fuchtbauer EM: M-twist is an inhibitor of muscle differentiation. Dev Biol. 165:537–544. 1994. View Article : Google Scholar : PubMed/NCBI
4.	Chen ZF and Behringer RR: Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev. 9:686–699. 1995. View Article : Google Scholar : PubMed/NCBI
5.	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Selamat SA, Galler JS, Joshi AD, et al: DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PloS One. 6:e214432011. View Article : Google Scholar : PubMed/NCBI
7.	Missaoui N, Hmissa S, Trabelsi A, et al: Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathol Res Prac. 207:37–42. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Renard I, Joniau S, van Cleynenbreugel B, et al: Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 58:96–104. 2010. View Article : Google Scholar
9.	Okada T, Suehiro Y, Ueno K, et al: TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer. 49:452–462. 2010.PubMed/NCBI
10.	Suehiro Y, Wong CW, Chirieac LR, et al: Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res. 14:2560–2569. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Santini V, Kantarjian HM and Issa JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Inter Med. 134:573–586. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Ohuchida K, Mizumoto K, Ohhashi S, et al: Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice. Int J Cancer. 120:1634–1640. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Gort EH, Suijkerbuijk KP, Roothaan SM, et al: Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev. 17:3325–3330. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Gort EH, van Haaften G, Verlaan I, et al: The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene. 27:1501–1510. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Yang MH, Wu MZ, Chiou SH, et al: Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 10:295–305. 2008. View Article : Google Scholar : PubMed/NCBI